ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…
News
Azilect (rasagiline) as an add-on therapy to Requip (ropinrole) improved sleep, reduced the need for sleep medications, and enhanced quality of life in a small group of people with Parkinson’s disease, a study suggested. These findings support more extensive studies to confirm the sleep-related benefits of Azilect,…
Over-expressing a fly gene called clueless (clu) can lessen mitochondrial defects in fruit fly models of Parkinson’s disease, a new study reveals. The results also showed that CLUH, the human equivalent of the fly clueless gene, has a similar function, which may pave the way toward new treatment approaches for…
A new app called NMS Assist, designed to remotely monitor the non-motor symptoms of Parkinson’s disease, is being developed and tested by researchers at Plymouth University in the U.K. The goal is to offer an application that can track non-motor symptoms — cognitive problems, mood changes, and fatigue,…
In 1817, James Parkinson published “An Essay on the Shaking Palsy,” the first such recognition of a disease that eventually would be known by his name. On April 11, World Parkinson’s Day and the 267th anniversary of Parkinson’s birth, and throughout the month, the Parkinson’s community will raise awareness about…
Vyant Bio and OrganoTherapeutics are teaming up to speed the discovery of new candidates for treating Parkinson’s disease. The collaboration will leverage OrganoTherapeutic’s patient-derived “mini-brains” — midbrain organoids — derived from induced pluripotent stem cells (iPSCs) and Vyant Bio’s expertise in machine learning technology to identify new…
ABBV-951, a continuous infusion formulation of levodopa/carbidopa, brought comparable levels of levodopa into the bloodstream of healthy volunteers as surgically implanted levodopa-carbidopa intestinal gel (LCIG), a Phase 1 study confirmed. Because the delivery of doses can be tailored to a patient’s needs, this alternative form of delivery — a portable…
The first patient has been dosed in a Phase 3 trial testing GE Healthcare’s new dopamine transporter positron emission tomography (PET) tracer, which is designed to aid in the evaluation of adults with suspected parkinsonian syndromes, including Parkinson’s disease. The PET agent is a…
IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement. The open-label trial…
Injecting acidic nanoparticles into mice in a model of Parkinson’s disease protected against nerve cell loss and restored the ability of lysosomes, cell compartments responsible for breaking down excess or damaged proteins, to work as they should, a research team reported. “Our results support lysosomal re-acidification as a disease-modifying strategy for…
Recent Posts
- MJFF grants totaling $7.6M will help Casma develop Parkinson’s therapy
- Planning is key when traveling with Parkinson’s disease
- I’m an optimist, but sometimes Parkinson’s fatigue is too much
- New smartphone platform helps doctors track Parkinson’s symptoms
- Camping can be a wonderful activity for those of us living with Parkinson’s